Global Nuclear Medicine Market report gives a comprehensive and detail picture of the present and upcoming market opportunities that is been completed by investigating the effect by buyers, new entrants, Nuclear Medicine industry competitors and suppliers available in the Nuclear Medicine market. The goal of this report is to incorporate both authentic and future trends for Nuclear Medicine supply, Market size, costs, exchanging, competition and value chain. The top to bottom information and data on what the business sectors definition, arrangements, applications, and commitment are covered and furthermore clarifies with the drivers and restraints of the market which is gotten from SWOT analysis.

This research essentially examines the market size, current trends and growth status of the Nuclear Medicine market, as well as financing opportunities, government policy, drivers, restraints, opportunities, supply chain, and ambitious landscape. Technological innovation and rise will additionally upgrade the presentation of the product, making it all the more generally utilized in downstream applications. Moreover, Porters Five Forces Analysis (potential entrants, suppliers, substitutes, buyers, industry competitors) provides vital data for knowing the Nuclear Medicine market.

Get Free Full Sample Report Including Detailed Analysis: @ https://www.globalmarketers.biz/report/life-sciences/global-nuclear-medicine-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/131303#request_sample

Major Players Of Nuclear Medicine Market

GE Healthcare, Bracco Imaging, Mallinckrodt, Lantheus Medical Imaging, Bayer, Triad Isotopes, Nordion, Jubilant Pharma, Eli Lilly, SIEMENS, China Isotope & Radiation, Dongcheng

This report covers the Types as well as Application data for Nuclear Medicine Market along with the country level information for the period of 2015-2024

Market Segmented By Types and By its Applications:

Type:Tc-99I-123/131In-111Xe-133Th-201Ga-67Other

Application:DiagnosticTherapeutic

Note: Upto 30% Discount: Get this reports in Discounted Price

Ask For Discount: https://www.globalmarketers.biz/discount_inquiry/discount/131303

Global Nuclear Medicine Market Scope and Features

Global Nuclear Medicine Industry Introduction and Overview Includes Nuclear Medicine market Definition, Market Scope and Market Size Estimation and region-wise Nuclear Medicine Value and Growth Rate history from 2015-2024, Nuclear Medicine market dynamics:Drivers, Limitations, challenges that are faced, emerging countries of Nuclear Medicine, Industry News and Policies by Regions.

Industry Chain Analysis To describe upstream raw material suppliers and cost structure of Nuclear Medicine, major players of Nuclear Medicine with company profile, Nuclear Medicine manufacturing base and market share, manufacturing cost structure analysis, Market Channel Analysis and major downstream buyers of Nuclear Medicine.

Global Nuclear Medicine Market Analysis by Product Type and Application It gives Nuclear Medicine market share, value, status, production, Nuclear Medicine Value and Growth Rate analysis by type from 2015 to 2019. Although downstream market overview, Nuclear Medicine consumption,Market Share, growth rate, by an application (2015-2019).

Regional Analysis This segment of report covers the analysis of Nuclear Medicine production, consumption,import, export, Nuclear Medicine market value, revenue, market share and growth rate, market status and SWOT analysis, Nuclear Medicine price and gross margin analysis by regions.

Competitive Landscape, Trends And Opportunities: It includes the provides competitive situation and market concentration status of major players of Nuclear Medicine with basic information i.e company profile, Product Introduction, Market share, Value, Price, Gross Margin 2015-2019

Nuclear Medicine Industry Analysis and Forecast by Region Includes Market Value and Consumption Forecast (2015-2024) of Nuclear Medicine market Of the following region and sub-regions including the North America, Europe(Germany, UK, France, Italy, Spain, Russia, Poland), China, Japan,Southeast Asia (Malaysia, Singapore, Philippines, Indonesia, Thailand, Vietnam) Middle East and Africa(Saudi Arabia, United Arab Emirates, Turkey, Egypt, South Africa, Nigeria), India, South America(Brazil, Mexico, Colombia)

Do you want any other requirement or customize the report, Do Inquiry Here: https://www.globalmarketers.biz/report/life-sciences/global-nuclear-medicine-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/131303#inquiry_before_buying

1 Nuclear Medicine Introduction and Market Overview

2 Industry Chain Analysis

3 Global Nuclear Medicine Value (US$ Mn) and Market Share, Production , Value (US$ Mn) , Growth Rate and Average Price (US$/Ton) analysis by Type (2015-2020)

4 Nuclear Medicine Consumption, Market Share and Growth Rate (%) by Application (2015-2020) by Application

5 Global Nuclear Medicine Production, Value (US$ Mn) by Region (2015-2020)

6 Global Nuclear Medicine Production (K Units), Consumption (K Units), Export (%), Import (%) by Regions (2015-2020)

7 Global Nuclear Medicine Market Status by Regions

8 Competitive Landscape Analysis

9 Global Nuclear Medicine Market Analysis and Forecast by Type and Application

10 Nuclear Medicine Market Analysis and Forecast by Region

11 New Project Feasibility Analysis

12 Research Finding and Conclusion13 Appendix13.1 Methodology13.2 Research Data Source

Table of Content & Report Detail @ https://www.globalmarketers.biz/report/life-sciences/global-nuclear-medicine-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/131303#table_of_contents

Original post:

Global Nuclear Medicine Market Size and Shares Forecasts till 2024 | Exclusively Available at GlobalMarketers - Daily Research Chronicles

By GILLIAN SLADE on July 16, 2020.

gslade@medicinehatnews.com

The City of Medicine Hat says the removal of a tree on Third Street downtown was to correct an issue that had occurred overnight.

Early Wednesday morning city parks and recreations crews were at work removing a tree at a pedestrian crossing downtown near 20/20 Vision.

Scott Richter, manager for parks and recreation, says the tree in question was removed because it had broken in half on Tuesday night.

For the observant who have noted that other trees have been removed downtown, this has only happened when the tree has been in bad condition or actually dead.

The only time we remove trees is if the health or hazard is present, said Richter.

The city does have plans to ultimately replace the trees.

Richter says there are plans to eventually upgrade the boulevards on Third Street, like the ones on Second Street were done in the last few years. The trees on Third Street will only be replaced when that work takes place.

You must be logged in to post a comment.

See the article here:

Broken tree removed from Third Street - Medicine Hat News

The Freemasons are one of the oldest and most well-known societies in the world. The have been the subject of numerous conspiracy theories throughout the years. Freemasonry evolved from the guilds of stonemasons and cathedral builders of the Middle Ages. Famous members of the society included Mozart, George Washington, Mark Twain, Winston Churchill and Franklin D Roosevelt.

Freemasons were once in great demand, and because of that they often took jobs that paid more than the market rate, according to the author Jasper Ridley. The first meeting of freemasons was held in an alehouse called Goose and Gridiron in the City of London. The many freemasons friends with whom I am in communication are fully in praise of a brotherhood that serves the people. However, not one of them has ever disclosed to me the rituals that they have to observe loose talk carry severe penalties.

Charity is one of the main tenets of Freemasonry. In the US alone, Freemasons collectively contribute millions of dollars every single day to charitable causes, including medical causes. During the First World War, the Freemasons built a hospital in the UK that treated more than 4,000 servicemen. When it outgrew its premises, a new hospital, called the Royal Masonic Hospital, was opened by King George V and Queen Mary. The architect, Thomas S Tait, was awarded a RIBA gold medal for his work in 1933.

The secret Kappa Lambda Society of Hippocrates, which existed in Lexington, Kentucky, during the first half of the 19th Century is also interesting. It was created for students of the Transylvania Universitys medical department. It promoted a code of ethics amongst doctors. Scottsdale, Arizona, is home to another secret medical society. Its membership is by invitation only; members trade secrets about automated ambulatory systems and hospitals call centres.

Medical symbols have been around as long as medicines. An excellent article by Anil Shetty et al in the Journal of Clinical and Diagnostic Research discusses medical symbols in practice. The Caduceus, or the Staff of Hermes astick entwined by two snakes and surmounted wings is the symbol of modern medicine in India and elsewhere. Hermes is the Greek god of wealth, luck and fertility, and is the patron god of the shepherd.

People associate the red cross which is the symbol of the International Red Cross Society with doctors. In actuality, the Rod of Asclepius, the god of medicine, should be our emblem. Asclepius was the son of Apollo (God of Light) and the sun. He is represented by a single serpent entwined around a staff. Anil Shettys article reveals that only 6 per cent of doctors are aware of the real symbol, the Rod of Asclepius. The UKs Royal College of Physicians has a coat of arms. It depicts a hand feeling a pulse and another hand descending from the heavens, indicating divine authority. It also has a pomegranate, the fruit of fertility and regeneration. It was chosen as a symbol because of its association with Henry the VIIIths first wife, Catherine of Aragon.

Secret societies raise interest because they are full of intrigue and excitement. Which one of us as a child, especially after reading Enid Blytons, The Secret Seven, has not tried or wished to belong to such a society. Much of medicine, a science full of mystery, is punctuated by anecdotes of such societies and interesting symbolism.

Originally posted here:

Secret societies and symbolism in medicine - Mumbai Mirror

At the onset of the coronavirus pandemic in March, Joanna Hart, a pulmonary and critical care physician at the Hospital of the University of Pennsylvania, and her teams livesnot to mention her familyschanged quickly and dramatically. Her job structure looked different, new safety and operational plans were in place, and, at home, she was juggling her career with caring for two young children with her husband.

That challenge felt especially acute when her children, a 7- and 3-year-old, were suddenly home from school and daycare.

I think that particularly women in academics are barely hanging on as it is, Hart, an assistant professor of medicine at the Perelman School of Medicine, explains. And then to have these increased family responsibilities and caregiver responsibilities you didnt anticipate, it felt like walking a tightrope. Like a potentially career-threatening thing to have happen.

Recognizing that, she says Penn reached out to employees like her early on to make PennMedicineTogether known as an available resource. PennMedicineTogether is a central web hub that provides resources in support of Penn Medicine staff. The website links to resources for physical health, access to life necessities, and means to care for their familiesplus, a thank-you page with notes from hundreds of Penn Medicine patients and their families.

For Hart, she says she was able to use the website as a way to connect her 7-year-old sonwho she emphasizes is very socialwith volunteer-facilitated, interactive activities to do through Zoom. He completed a theater program and a session of charades.

I really appreciate that Penn put real thought and resources into making sure people who have kids at home are able to sneak in work time and have provided whatever resources they could in a virtual environment, to support child care and allow me to do meetings and write for 45 minutes, Hart says. And get my workday back.

Were all in this together, and I think thats our most important message. Were here to help each other navigate what is the rest of this crisis. Lisa Bellini, senior vice dean for academic affairs at the Perelman School of Medicine

Lisa Bellini, senior vice dean for academic affairs at the Perelman School of Medicine, credits the success of PennMedicineTogetherit has already accrued more than 91,000 page views and 32,000 usersto Penn Medicines resilient spirit, from the get-go. Planning for the pandemic, at-large, began as early as December, she says, while approximately 20 staff members came together quickly at the onset of the pandemic to create PennMedicineTogether as a staff resource.

People really just came to the table with these wide agendas of, We cant leave until we figure this out, Bellini says. And it was incredibleits still incredible. And part of PennMedicineTogether is giving people the resources to stay resilient, recognizing that we are all going to deal with the anxiety and uncertainty [of the virus] in different ways. Some of this is normalizing the fact that we all have some anxiety and its going to be expressed a little differently in all of us.

Work on PennMedicineTogether began in the third week of March and was launched two weeks later. The mission: to broadly develop new resources and integrate ones that already existed and scale them. Perspectives were sure to include and focus on behavioral health, psychology, and innovation.

I feel good about the progress weve made since this launched, says Stephanie Taitano, director of faculty professional development at Penn Medicine.

Taitano sits on a Wellness Committee that contributes to the development of PennMedicineTogether.

Its been incredible to see the kinds of generosity in the community, from Philly vendors and individuals who want to offer goods and services and words of thanks and gratitude, she says. One of the most popular pages by far is the gratitude page, where people go to not only look at the messages but also submit their own and their images of gratitude.

Many of the sites features and initiatives, she adds, have been ideas submitted by the Penn community. Among examples: a volunteer program that coordinates meals to be delivered to frontline workers, and the kids programming Hart used for her 7-year-old son.

Integral to PennMedicineTogether as a resource is PennCOBALT, a new web-based platform developed in the early weeks of the crisis that matches health care workers to mental health resources and the appropriate level of group and individual mental health and well-being support. It culls a list of potential providers by asking participants to answer questionsthat is, before even entering the appabout their needs in a quick survey format, allowing for targeted care. Its curated compassion.

Everyone is overwhelmed with a barrage of information right now and, even in the best of circumstances, mental health care is challenging to navigate and tends to be generalized, says Cecilia Livesey, chief of integrated services in psychiatry at Penn Medicine and creator of the app, explaining that patients are often pointed to a psychiatrist or therapist in an overly broad way. If you had a torn ACL requiring surgery, you wouldnt want to go to a primary care physician, but often people with a treatable mental illness requiring evidence-based care from a specialist end up seeing multiple providers before they land in the right place. Were really trying to be targeted and get people to the right type and level of care from the get go.

Visitors to the COBALT web app are also shown content tailored to how they answered initial questions. For those not seeking one-on-one care, there are meditation tools, groups to help process traumacrucial to preventing PTSDand an option to create your own group. Additionally, there are podcasts, worksheets, videos, and more. The app is so-named after cobalt as an adaptable metal, as well as a trace element thats essential for neurological health.

Importantly, the app gives users the ability to remain anonymous while using the site, and there is an In Crisis button for those considering self-harm.

Those acute cases where people have safety concerns with people identifying and acting on this has been really critical, Livesey says.

Thea Gallagher, assistant professor of psychology and outpatient clinic director at the Center for the Treatment and Study of Anxiety in Psychiatry, has volunteered to facilitate processing groups. Some workers come to the group having suddenly taken on a role of a first responder without ever thinking they would, and others feel stress over wanting to do more or feeling overwhelmed. There are also many shes worked with, she says, whove experienced exacerbated mental health conditions like anxiety and OCD.

Those people are concerned about contaminating other people, or dying, or worrying in general about their loved ones or feeling uncertain, Gallagher explains. So, I think there are people who were already feeling like this is an anxious time, and yet there are also people who already struggle with anxiety and are struggling even more.

Others, she says, have been redeployed to different jobs within the Health System and are working to manage a new set of stressors associated with that transition. She tries to promote reflection on feelings, coping strategies, self-care, social support, and management of catastrophic thinking. These are essential to making this overwhelming work sustainable for the long-termEspecially as the pandemic is ongoing, she says.

Bellini describes the more seamlessand normalizedapproach to mental health care access through COBALT a game-changer.

I think what weve stumbled upon is a new way of delivering mental health services, period, she says. One of the most interesting parts of this is you can connect to mental health care in a HIAA-compliant way in the privacy of your own home. You dont need to call somebody and describe your situation, to be triaged and get a call back and make an appointment you dont need to show up in a psychologist or psychiatrist waiting room and register, and sit there and get called backtheres none of that. This is all virtual and, honestly, I think this is a model of how to transform mental health care delivery and reduce barriers to care, which is important to this vulnerable workforce.

The resource will stay in place indefinitely, says Taitano. Bellini, meanwhile, expresses a hearty thanks to the Penn Medicine community for their time, spirit, energy, and compassion to patients.

Were all in this together, and I think thats our most important message, Bellini says. Were here to help each other navigate what is the rest of this crisis.

Homepage photo: PennMedicineTogether is a central web hub that provides resources in support of Penn Medicine staff. The website links to resources for physical health, access to life necessities, and means to care for their families.

See more here:

Web-based platforms provide supporting resources for Penn Medicine staff - Penn: Office of University Communications

GILBERT, Ariz.--(BUSINESS WIRE)--The National Academy of Sports Medicine (NASM), the worldwide leader in fitness, performance, and corrective exercise education, has partnered with the National Basketball Athletic Trainers Association (NBATA) to become its official education partner.

The Athletic Trainers that make up the NBATA work with some of the greatest athletes in the world, and they require the highest standards for evidence-based training methodologies, said Laurie McCartney, President of the National Academy of Sports Medicine. Through this exciting collaboration, NBATA Athletic Trainers will have direct access to the industrys most respected and innovative education programs for developing elite athletes.

As a longtime advocate for and user of NASM education, I know how effective and beneficial the NASM Corrective Exercise and Performance Enhancement Specializations are for athletic training, said Aaron Nelson, Chairman of the National Basketball Athletic Trainers Association and Vice President of Player Care and Performance for the New Orleans Pelicans. NASM education has long been valued amongst our membership, so this partnership is a natural fit.

The NASM Corrective Exercise Specialization (NASM-CES) helps Athletic Trainers program unique and effective workouts tailored to the individual athlete. By leveraging the principles taught inside CES, Athletic Trainers can safely and effectively help athletes move better, avoid injuries, and recover faster.

The NASM Performance Enhancement Specialization (NASM-PES) teaches evidence-based techniques that maximize performance and build stronger, faster, and more resilient athletes.

Both courses are 100% online, which allows for flexible learning schedules that fit into a busy Athletic Trainers lifestyle.

Another element of the long-term partnership between NBATA and NASM will be creating a steering committee in which members from both organizations will work together to develop thought leadership for ongoing optimizations and innovations in fitness and athletic training.

About NASM: Now in its 33rd year, the National Academy of Sports Medicine (NASM) has remained the international standard in fitness education due to the high quality of fitness professionals they produce and the scientific rigor of their programs. NASM offers a best in class Certified Personal Training program along with major specializations in Nutrition Coaching (CNC), Sports Performance (PES), and Corrective Exercise (CES).

About NBATA: The NBATA is a professional organization of highly skilled certified athletic trainers who provide specialized health care, performance, and critical support services to the athletes and organizations of the National Basketball Association. Members are committed and uniquely qualified to lead the management of exceptional health care, provide dynamic performance insights, and conduct basketball-related sports medicine research to benefit our athletes and our communities. The NBATAs members uphold the athletic training professions highest moral and ethical standards. For more information about the NBATA, visit http://www.nbata.com.

See more here:

The National Academy of Sports Medicine (NASM) Becomes the Official Education Partner for the NBA Athletic Trainers Association (NBATA) - Business...

Mon, Jul 13, 2020

Event RecapbyHenry Westerman

Related Experts: David Bray, PhD,

On Thursday, June 18, 2020, the Atlantic CouncilsGeoTechCenter andNanotronicshosted YvesDaccord, Former Director General of the International Committee of the Red Cross, Philippe Gillet, Chief Scientific Officer of SIPCA, Toomas HendrikIlves, former President of the Republic of Estonia, IdrisGuessous, MD and PhD, Head of the Division of Primary Care Medicine at the University Hospitals of Geneva, PeterRashish, Senior Fellow and Director of theGeoeconomicsProgram at the American Institute for Contemporary German Studies, DanielleTavino, VP and Co-Founder of Code-X, andDr. DivyaChander, MD and PhD, CEO and Founder oflucidify.

The event wasmoderatedby David Bray, PhD,Director of theGeoTechCenter at the Atlantic Council.

The paneldiscussedthe potential for technological and policy innovationstoenable a greater degree of trust between medical organizations and supply chain providers by following the example of some of the worlds best practitioners.

Personal and public health,as well as the care and medicine required to maintainthem,have always been top priorities for individuals and societies around the world. Amidst the COVID-19pandemic, concernsoverhealth havebecome even more prevalent. Yet, as the panel responded, at the same timeas more people than ever are seeking reliable information andmeasures to protect themselves from the novel coronavirus,healthcare systemsin the UnitedStatesand other countriesareconfronting a crisis of trustemerging in three key ways.

Thepanel emphasizedthe way that, as withall issues of trust,the primary difficultiesareon a personal level.Individuals have found it increasingly difficult todetermine thetrustworthiness ofmedical advicefor dealing with COVID-19. With so muchdisinformationand somany false-but-enticing medical messages floating around themediasphere, ordinary citizensfindit harder than ever toknowwhether recommendationsfrom neighbors, medical professionals, or politicianswill actually protect their health.

Relatedly, medical practitioners themselves have increasingly struggled with trusting the information coming to them from researchers, policymakers, and administrators.The paneldecried that,whether it be a high-profile scandal at prestigiousmedical journals like the Lancet, or a smaller-scale policymix-upor data flaw, doctors struggle to find trustworthyguidelinesto inform theirmedical decisions.

On a systemic level, the medical supply chainrecentlyencounteredserious problemsasindustriesfound their complex, globalsupply chains disrupted by local and international crises. In the name of efficiency, hospitals have outsourced the productionofessential tools, ranging from personal protective equipment (PPE) or respirators topharmaceuticals. Unfortunately, with such adispersed supply chain, itisnearly impossible for hospitals and medical systems to accurately identify their real carrying capacity in times of crisis when many healthcare providers find themselves relying on the same limited suppliers, resulting inunexpectedshortages.

The panel explainedthat, due to the breakdown of trust in the medical system at all three of these levels, the world has failed to effectively respond to COVID-19. Individuals have found themselves unsure of who to trust for medical advice. Doctors are at a lossaboutwhere togetreliable information on the growing pandemic. And hospitals and medical systems have run into shortages andare unabletoutilize theirsurge capacity due to the complexity of theirsupply chains.

Fortunately, the panel advised, new technological tools can help to restore trust in the medical system ateachof these levels. Through the implementation of a data trust for medical and health related information, as envisioned by theGeoTechCenter, researchers couldaccesshard datawhilethe studied individualsremaincertainthat their privacy is notcompromised.Adata trust systemdeveloped by a coalition of public, private, and NGO partners and maintained bycitizen-juriesand transparent regulationscanrestore thesacred trust between medical researchers and practitioners and patients. This framework could store data beyond biometrics as well, including records of suppliers and their sources of devices and equipment, tostreamlinein the medical supply chain.

According to the panels vision, a data trustwouldalso enable individuals to take ownership of their data, deciding how and by whom it can be used. Consideringthetransferof data a transaction in which the individual has equal agency will help build trust in both the dataprovidedand the conclusions drawn from it, as individuals couldchoose to only provide their data to projects that would benefit the commongood.The unified framework of alarge-scaledata collection of this nature would also facilitate easy transfer of information and ideas across communities, states, and nations. In this way, the panel envisionedan economy of trust in health data that couldspread to the entire world, helping build networks of trusted partners within communities and globally. With every medical and data transaction made transparent through the use of technology, medical practitioners couldbridge the gap between patients, doctors, and researchers, restoring lost trust through virtually-enabled person-to-person interaction.

Some of the worlds most advanced medical systems have already begun to develope a system-level data trustor other frameworks for building trust in medicine.

One of the most frequently celebrated examples in recent years has been the country of Estonia, whose esteemed former President, Toomas HendrikIlves,outlined their medical technology innovations for the panel. In Estonia, all medical records and biometric informationarekept on a keyless signature blockchainthrough whichcitizens are granted individual ownership over their data, who accessesit, and for what reasons. The systems design also insulates against potential data manipulation and corruption, meaning doctors and researchers can trust the integrity of the data theyreceive. With high levels of protected data maintainedforevery citizen, Estonia can more effectively prepare for health crises and provide individualized care as needed.

Anotheroft-cited exampleofpervasivesocietaltrustis Switzerland, represented by IdrisGuessous, MD and PhD,of the University Hospitals of Geneva. Though Switzerland is respected around the world foritshighcitizen participation in government, as well asitslow levels of inequality, the UHG system has also begunrollingout technological tools for building trust between citizens, their doctors, and the researchers studying there. Dr.Guessousemphasized how, as the hospital rolled out digitized medical recordsthroughwhichpatientswereasked before their data could be studied, he was surprised by the number of patients who consented to their datas use,so long as their information could be leveragedfor the public good. The panel emphasizedthatmost individuals would be more than willing to provide their data to doctors and researchers,so long as theycouldtrust that the goalsofits use are transparent and worthwhile.

As these examples illustrate, it is technologically feasible even now to develop adata trustakin to the panels vision. Theobstacle, though, is whetherrelevant parties can cooperatetodevelopa system that empowers citizens and builds trust, rather than one that emphasizes individualism, surveillance, and one-sided transactions.

Henry Westerman is an intern with the Atlantic Councils GeoTech Center and a rising senior at Georgetown Universitys School of Foreign Service. His course of study is in Science, Technology, and International Affairs, with a concentration in Security, focusing on the intersection of science and geopolitics, particularly relating to advanced digital infrastructure and outer space development. Previously, Henry has interned at the Library of Congress and the Department of States Office of Science and Technology Cooperation. He also works at Georgetowns writing center, providing free editing and consultations and serves as the historian for Georgetowns student association.

Read more from the original source:

Event recap: Increasing resilience by assuring trust in medicine, credentials, and supply chains - Atlantic Council

Medicine is so costly that the poor cant bear the heavy prices. Consequently, a majority of the poor die because of a lack of proper treatment and medicine. The price of medicine is highly expensive in Pakistan which contributes to the deterioration of health in low-income families. It is quite normal in public hospitals, especially in Sindh, that doctors recommend private medicine to their patients. To ask doctors about governmental medicine is a waste of time; they continuously blame the government for the lack of medicine.

People, who are well-off and opulent, often try to consult private doctors and take medicines they suggest. However, the poor mainly depend on public hospitals and dispensaries, but a lack of medicine in government hospitals has contributed a lot in making the situation worse for them. Currently, COVID-19 and the high rate of inflation have undoubtedly been a great burden on the pocket of the poor. To survive in this hellacious situation is beyond the poors capability.

Therefore, the government of Pakistan should play its role in making things easier for the poor. The proper set up of medicine in public hospitals and dispensaries should be assured. Likewise, the government should also bring down the cost of private medicine at an accessible level for the poor.

IMTIAZ ESSA HALEPOTO,

Jamshoro.

See the original post:

Costly medicine - The Nation

Global Traditional Chinese Medicine for COVID-19 Market Report provides complete industry analysis, market outlook, size, growth, opportunities and forecast 2025. This report will assist in analyzing the current and future business trends, sales and revenue forecast. It provides top manufacturers information along with Manufacturing Cost Analysis, Industrial Chain, Sourcing Strategy and growth.

The Traditional Chinese Medicine for COVID-19 market is an intrinsic study of the current status of this business vertical and encompasses a brief synopsis about its segmentation. The report is inclusive of a nearly accurate prediction of the market scenario over the forecast period market size with respect to valuation as sales volume. The study lends focus to the top magnates comprising the competitive landscape of Traditional Chinese Medicine for COVID-19 market, as well as the geographical areas where the industry extends its horizons, in magnanimous detail.

Request a sample Report of Traditional Chinese Medicine for COVID-19 Market at:https://www.marketstudyreport.com/request-a-sample/2619249?utm_source=coleofduty.com&utm_medium=Ram

A rundown of the competitive spectrum:

.

Unveiling the regional landscape:

An outline of the Traditional Chinese Medicine for COVID-19 market segmentation:

.

.

Ask for Discount on Traditional Chinese Medicine for COVID-19 Market Report at:https://www.marketstudyreport.com/check-for-discount/2619249?utm_source=coleofduty.com&utm_medium=Ram

Pivotal highlights of Traditional Chinese Medicine for COVID-19 market:

The Traditional Chinese Medicine for COVID-19 market report enumerates quite some details about the factors impacting the industry, influence of technological developments on the vertical, risks, as well as the threats that substitutes present to the industry players. In addition, information about the changing preferences and needs of consumers in conjunction with the impact of the shifting dynamics of the economic and political scenario on the Traditional Chinese Medicine for COVID-19 market has also been acknowledged in the study.

For More Details On this Report: https://www.marketstudyreport.com/reports/global-traditional-chinese-medicine-for-covid-19-market-research-report-2020

Related Reports:

1. Global Smart Manufacturing Platform Market Size, Status and Forecast 2020-2025Read More: https://www.marketstudyreport.com/reports/global-smart-manufacturing-platform-market-size-status-and-forecast-2020-2025

2. Global 5G Applications and Services Market Size, Status and Forecast 2020-2025Read More: https://www.marketstudyreport.com/reports/global-5g-applications-and-services-market-size-status-and-forecast-2020-2025

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Read the original here:

Traditional Chinese Medicine for COVID-19 Market: Technological Advancement & Growth Analysis with Forecast to 2025 - Cole of Duty

The government has previously said that starting from autumn, a 1+1 rule of coronavirus management will be applied if an institution has experienced cases of COVID-19. This means that the institution has to manage the first month with their own equipment, the state will support them starting in the second month, if necessary.

Andras Banyasz, chief specialist of Emergency Medicine of Health Board, said the current supply of equipment and medicine is not enough.

Banyasz said: "The Health Board manages the current state supply of healthcare equipment and it would not last a month. The Ministry of Finance has started to collect PPE nationally, that equipment will arrive."

The same can be said for medicine for emergency situations. But those can not be acquired before the new year.

Banyasz said: "We have not been allocated resources to acquire medicine, but we will keep applying for it and there's a chance next year, that we can resupply on medicine."

ERR News wrote on July 7 that Estonia has ordered 400 doses of an antiviral drug called remdesivir through a joint European Union procurement.

Former Health Board Director General Merike Jrilo said in May that the institution would need funding to staff some 20 additional positions in various fields of the Health Board's activities. Jrilo, along with two other employees have left, but no additional workforce has been hired yet.

Banyasz said the Health Board has asked for resources to hire analysts. "Truthfully, we are indeed missing about 20 people to be prepared for any next crises. We need more analysts so we could efficiently analyse data as we go. That proposal awaits government's response and approval."

Based on the infection rate, travelers from Sweden, Portugal, Romania, Bulgaria, Croatia, Czech Republic, Luxembourg, Montenegro and Serbia must self-isolate for 14 days when entering Estonia.

Banyasz said there is no direct surveillance conducted, self-isolation is based on trust and is volunatry. "The goal of it is to stop the spread domestically."

--

Download the ERR News app for Android and iOS now and never miss an update!

Follow this link:

Health Board short on PPE and medicine for possible second wave of COVID-19 - ERR News

New Jersey, United States,- Latest update on Prostate Cancer Nuclear Medicine Diagnostics Market Analysis report published with extensive market research, Prostate Cancer Nuclear Medicine Diagnostics Market growth analysis, and forecast by 2026. this report is highly predictive as it holds the overall market analysis of topmost companies into the Prostate Cancer Nuclear Medicine Diagnostics industry. With the classified Prostate Cancer Nuclear Medicine Diagnostics market research based on various growing regions, this report provides leading players portfolio along with sales, growth, market share, and so on.

The research report of the Prostate Cancer Nuclear Medicine Diagnostics market is predicted to accrue a significant remuneration portfolio by the end of the predicted time period. It includes parameters with respect to the Prostate Cancer Nuclear Medicine Diagnostics market dynamics incorporating varied driving forces affecting the commercialization graph of this business vertical and risks prevailing in the sphere. In addition, it also speaks about the Prostate Cancer Nuclear Medicine Diagnostics Market growth opportunities in the industry.

Prostate Cancer Nuclear Medicine Diagnostics Market Report covers the manufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including Prostate Cancer Nuclear Medicine Diagnostics market size, volume and value, as well as price data.

Prostate Cancer Nuclear Medicine Diagnostics Market competition by top Manufacturers:

Prostate Cancer Nuclear Medicine Diagnostics Market Classification by Types:

Prostate Cancer Nuclear Medicine Diagnostics Market Size by End-user Application:

Listing a few pointers from the report:

The objective of the Prostate Cancer Nuclear Medicine Diagnostics Market Report:

Cataloging the competitive terrain of the Prostate Cancer Nuclear Medicine Diagnostics market:

Unveiling the geographical penetration of the Prostate Cancer Nuclear Medicine Diagnostics market:

The report of the Prostate Cancer Nuclear Medicine Diagnostics market is an in-depth analysis of the business vertical projected to record a commendable annual growth rate over the estimated time period. It also comprises of a precise evaluation of the dynamics related to this marketplace. The purpose of the Prostate Cancer Nuclear Medicine Diagnostics Market report is to provide important information related to the industry deliverables such as market size, valuation forecast, sales volume, etc.

Major Highlights from Table of contents are listed below for quick lookup into Prostate Cancer Nuclear Medicine Diagnostics Market report

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Read more from the original source:

Prostate Cancer Nuclear Medicine Diagnostics Market Size By Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies And...

This Medicine for the Treatment of Advanced Thyroid Cancer Industry report provides details of recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, strategic market growth analysis, and market size. The report also offers insightful and detailed information regarding the various key players operating in the global Medicine for the Treatment of Advanced Thyroid Cancer market, and their financials, apart from strategies, acquisitions & mergers, and market footprint. The global Medicine for the Treatment of Advanced Thyroid Cancer market is segmented on the basis of component, application, and region.

Request for PDF Brochure:

https://www.marketinsightsreports.com/reports/07132141792/global-medicine-for-the-treatment-of-advanced-thyroid-cancer-market-research-report-2020/inquiry?Mode=21

Top Leading Manufacturers:

Bayer, AstraZeneca, Sanofi, Exelixis Inc., Ipsen Pharma, Eisai Inc

Market size by ProductCabozantinib

Sorafenib

Vandetanib

Lenvatinib

Market size by End UserCombination therapy

Solo Medication

Contents of the 15 Chapters for This Medicine for the Treatment of Advanced Thyroid Cancer Market Study:-

Chapter 1 provides an overview of Medicine for the Treatment of Advanced Thyroid Cancer market, containing global revenue, global production, sales, and CAGR. The forecast and analysis of market by type, application, and region are also presented in this chapter.

Chapter 2 is about the market landscape and major players. It provides competitive situation and market concentration status along with the basic information of these players.

Chapter 3 provides a full-scale analysis of major players in Medicine for the Treatment of Advanced Thyroid Cancer industry. The basic information, as well as the profiles, applications and specifications of products market performance along with Business Overview are offered.

Chapter 4 gives a worldwide view of Medicine for the Treatment of Advanced Thyroid Cancer market. It includes production, market share revenue, price, and the growth rate by type.

Chapter 5 focuses on the application of Medicine for the Treatment of Advanced Thyroid Cancer, by analyzing the consumption and its growth rate of each application.

Chapter 6 is about production, consumption, export, and import of Medicine for the Treatment of Advanced Thyroid Cancer in each region.

Chapter 7 pays attention to the production, revenue, price and gross margin of Medicine for the Treatment of Advanced Thyroid Cancer in markets of different regions. The analysis on production, revenue, price and gross margin of the global market is covered in this part.

Chapter 8 concentrates on manufacturing analysis, including key raw material analysis, cost structure analysis and process analysis, making up a comprehensive analysis of manufacturing cost.

Chapter 9 introduces the industrial chain of Medicine for the Treatment of Advanced Thyroid Cancer. Industrial chain analysis, raw material sources and downstream buyers are analyzed in this chapter.

See More

Browse the Full report description and TOC at:

https://www.marketinsightsreports.com/reports/07132141792/global-medicine-for-the-treatment-of-advanced-thyroid-cancer-market-research-report-2020?Mode=21

Market Size Estimation:

In the complete market engineering process, both top-down and bottom-up approaches have been implemented, along with several data triangulation methods, to estimate and validate the size of the smart ticketing market and other dependent submarkets listed in this report.

The key players in the industry and markets have been identified through extensive secondary research.

The industrys supply chain and market size, in terms of value, have been determined through primary and secondary research processes.

All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Note: All the reports that we list have been tracking the impact of COVID-19 the market. Both upstream and downstream of the entire supplychain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

Customization of this Report:This Speech Intelligibility Device report could be customized to the customers requirements. Please contact our sales professional ([emailprotected]), we will ensure you obtain the report which works for your needs.

Contact US :

Irfan Tamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234

Mob: +91-750-707-8687

See more here:

Medicine for the Treatment of Advanced Thyroid Cancer Market Clinical Research Analysis Report 2020-2026 - Cole of Duty

Representative image. Photo: Julie Viken/Pexels.

Once defined in rhetorical but ultimately meaningless terms as the conscientious, judicious and explicit use of current best evidence in making decisions about the care of individual patients [1], evidence-based medicine rests on certain philosophical assumptions: a singular truth, ascertainable through empirical enquiry; a linear logic of causality in which interventions have particular effect sizes; rigour defined primarily in methodological terms (especially, a hierarchy of preferred study designs and tools for detecting bias); and a deconstructive approach to problem-solving (the evidence base is built by answering focused questions, typically framed as PICO population-intervention-comparison-outcome) [2].

The trouble with pandemics is that these assumptions rarely hold. A pandemic-sized problem can be framed and contested in multiple ways. Some research questions around COVID-19, most notably relating to drugs and vaccines, are amenable to randomised controlled trials (and where such trials were possible, they were established with impressive speed and efficiency [3, 4]). But many knowledge gaps are broader and cannot be reduced to PICO-style questions. Were care home deaths avoidable [5]? Why did the global supply chain for personal protective equipment break down [6]? What role does health system resilience play in controlling the pandemic [7]? And so on.

Against these and other wider questions, the neat simplicity of a controlled, intervention-on versus intervention-off experiment designed to produce a definitive (i.e. statistically significant and widely generalisable) answer to a focused question rings hollow. In particular, upstream preventive public health interventions aimed at supporting widespread and sustained behaviour change across an entire population (as opposed to testing the impact of a short-term behaviour change in a select sample) rarely lend themselves to such a design [8, 9]. When implementing population-wide public health interventions whether conventional measures such as diet or exercise, or COVID-19 related ones such as hand-washing, social distancing and face coverings we must not only persuade individuals to change their behaviour but also adapt the environment to make such changes easier to make and sustain [10, 11, 12].

Population-wide public health efforts are typically iterative, locally-grown and path-dependent, and they have an established methodology for rapid evaluation and adaptation [9]. But evidence-based medicine has tended to classify such designs as low methodological quality [13]. Whilst this has been recognised as a problem in public health practice for some time [11], the inadequacy of the dominant paradigm has suddenly become mission-critical.

Whilst evidence-based medicine recognises that study designs must reflect the nature of question (randomised trials, for example, are preferred only for therapy questions [13]), even senior scientists sometimes over-apply its hierarchy of evidence. An interdisciplinary group of scholars from the UKs prestigious Royal Society recently reviewed the use of face masks by the general public, drawing on evidence from laboratory science, mathematical modelling and policy studies [14]. The report was criticised by epidemiologists for being non-systematic and for recommending policy action in the absence of a quantitative estimate of effect size from robust randomised controlled trials [15].

Such criticisms appear to make two questionable assumptions: first, that the precise quantification of impact from this kind of intervention is both possible and desirable, and second, that unless we have randomised trial evidence, we should do nothing.

It is surely time to turn to a more fit-for-purpose scientific paradigm. Complex adaptive systems theory proposes that precise quantification of particular cause-effect relationships is both impossible (because such relationships are not constant and cannot be meaningfully isolated) and unnecessary (because what matters is what emerges in a particular real-world situation). This paradigm proposes that where multiple factors are interacting in dynamic and unpredictable ways, naturalistic methods and rapid-cycle evaluation are the preferred study design. The 20th-century logic of evidence-based medicine, in which scientists pursued the goals of certainty, predictability and linear causality, remains useful in some circumstances (for example, the drug and vaccine trials referred to above). But at a population and system level, we need to embrace 21st-century epistemology and methods to study how best to cope with uncertainty, unpredictability and non-linear causality [16].

In a complex system, the question driving scientific inquiry is not what is the effect size and is it statistically significant once other variables have been controlled for? but does this intervention contribute, along with other factors, to a desirable outcome?. Multiple interventions might each contribute to an overall beneficial effect through heterogeneous effects on disparate causal pathways, even though none would have a statistically significant impact on any predefined variable [11]. To illuminate such influences, we need to apply research designs that foreground dynamic interactions and emergence. These include in-depth, mixed-method case studies (primary research) and narrative reviews (secondary research) that tease out interconnections and highlight generative causality across the system [16, 17].

Table 1 lists some philosophical contrasts between the evidence-based medicine and complex-systems paradigms. Ogilvie et al have argued that rather than pitting these two paradigms against one another, they should be brought together [9]. As illustrated in (Fig. 1), these authors depict randomised trials (what they call the evidence-based practice pathway) and natural experiments (the practice-based evidence pathway) in a complementary and recursive relationship rather than a hierarchical one. They propose that intervention studies [e.g. trials] should focus on reducing critical uncertainties, that non-randomised study designs should be embraced rather than tolerated and that a more nuanced approach to appraising the utility of diverse types of evidence is required. (page 203) [9].

In the current fast-moving pandemic, where the cost of inaction is counted in the grim mortality figures announced daily, implementing new policy interventions in the absence of randomised trial evidence has become both a scientific and moral imperative. Whilst it is hard to predict anything in real time, history will one day tell us whether adherence to evidence-based practice helped or hindered the public health response to COVID-19 or whether an apparent slackening of standards to accommodate practice-based evidence was ultimately a more effective strategy.

Trisha Greenhalgh is a professor of primary care health sciences atNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford.

This article was published as an editorial on PLOS Medicine and has been republished here under a Creative Commons Attribution license.

Continued here:

Will COVID-19 Be Evidence-Based Medicine's Nemesis? - The Wire

New Jersey, United States,- Latest update on Radiopharmaceuticals in Nuclear Medicine Market Analysis report published with extensive market research, Radiopharmaceuticals in Nuclear Medicine Market growth analysis, and forecast by 2026. this report is highly predictive as it holds the overall market analysis of topmost companies into the Radiopharmaceuticals in Nuclear Medicine industry. With the classified Radiopharmaceuticals in Nuclear Medicine market research based on various growing regions, this report provides leading players portfolio along with sales, growth, market share, and so on.

The research report of the Radiopharmaceuticals in Nuclear Medicine market is predicted to accrue a significant remuneration portfolio by the end of the predicted time period. It includes parameters with respect to the Radiopharmaceuticals in Nuclear Medicine market dynamics incorporating varied driving forces affecting the commercialization graph of this business vertical and risks prevailing in the sphere. In addition, it also speaks about the Radiopharmaceuticals in Nuclear Medicine Market growth opportunities in the industry.

Radiopharmaceuticals in Nuclear Medicine Market Report covers the manufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including Radiopharmaceuticals in Nuclear Medicine market size, volume and value, as well as price data.

Radiopharmaceuticals in Nuclear Medicine Market competition by top Manufacturers:

Radiopharmaceuticals in Nuclear Medicine Market Classification by Types:

Radiopharmaceuticals in Nuclear Medicine Market Size by End-user Application:

Listing a few pointers from the report:

The objective of the Radiopharmaceuticals in Nuclear Medicine Market Report:

Cataloging the competitive terrain of the Radiopharmaceuticals in Nuclear Medicine market:

Unveiling the geographical penetration of the Radiopharmaceuticals in Nuclear Medicine market:

The report of the Radiopharmaceuticals in Nuclear Medicine market is an in-depth analysis of the business vertical projected to record a commendable annual growth rate over the estimated time period. It also comprises of a precise evaluation of the dynamics related to this marketplace. The purpose of the Radiopharmaceuticals in Nuclear Medicine Market report is to provide important information related to the industry deliverables such as market size, valuation forecast, sales volume, etc.

Major Highlights from Table of contents are listed below for quick lookup into Radiopharmaceuticals in Nuclear Medicine Market report

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Original post:

Radiopharmaceuticals in Nuclear Medicine Market Size By Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies And...

(A version of this story first appeared on Marijuana Business Daily.)

Peru is giving hemp-derived medicines the green light, with commercialization imminent once the respective companies obtain the necessary import permits.

Two hemp-derived products are registered as cannabis-derived natural health products in Peru.

Toronto-headquartered Ramm Pharma, a company with medical cannabis manufacturing operations in Uruguay, said last week that the Peruvian Ministry of Health approved its Epifractn 5% CBD product for sale in pharmaciesthroughout the country for various indications as prescribed by a medical doctor.

Peruvian CannFarm will be the local distributor of Epifractn.

Peru has only one other registered cannabis-derived natural health product and it belongs to Canada-based Canopy Growth. Both products have CBD as the active ingredient, with minimum or no detectable THC, but can be sold only by medical prescription.

Niklaus Schwenker, director of communications and strategy for Canopy Growth Latin America, told Hemp Industry Daily that Peru has one of the most advanced regulations for cannabis in Latin America and is a priority for the Canopy Growth in the region.

With product approval already in place, the company expects to serve Peruvian patients in the near term while continuing its physician-education activities through the Spectrum Academy, Schwenker said.

Companies with registered products must obtain the necessary import permits to be able to receive the shipments and distribute to pharmacies around the country, Andres Vazquez Vargas, CEO of CannFarm Peru, told Hemp Industry Daily.

After obtaining the import permit, we expect to receive the first shipment from Uruguay and start distributing to patients in Peru in the next weeks, Vazquez said.

Ramm Pharma has been selling the product by doctors prescription in Uruguayan pharmacies since 2018.

Epifractn is also sold in other countries of the region, such as Brazil and Argentina, under compassionate use cannabis programs, which generally means the Uruguayan company ships case-by-case to specific authorized patients.

As of July 10, the public database of the Peruvian health authority showed 17 product registrations were submitted by six companies and were pending approval.

This is in addition to Sativex, a marijuana-derived treatment for multiple sclerosis. Sativex is manufactured by GW Pharmaceuticals in the United Kingdom and was approved as a cannabis-derived pharmaceutical.

Alfredo Pascual can be reached at[emailprotected]

View post:

Peru opens the door to CBD medicines, with commercialization imminent - Hemp Industry Daily

Written by Dr Satchit Balsari, Dr Zarir Udwadia | New Delhi | Updated: July 14, 2020 8:03:55 am

Like a wedding guest piling food from a buffet onto their plate until there is no place left, doctors have been prescribing fistfuls of drugs when attempting to manage patients with Covid-19. We summarise based on current evidence from around the world, what scientists say works and does not, from among the treatments currently in vogue in India.

Azithromycin: This must be the most widely prescribed and misused antibiotic in this pandemic. Azithromycin, as with all other antibiotics, does not work in viral infections. Antibiotics are only warranted in patients who have evidence of a secondary bacterial infection as some hospitalised patients will have in the later stages of their disease. Indiscriminate use (as was the case even before the pandemic) in the hope that they will prevent bacterial infection only worsens antibiotic resistance, to which India is a frequent contributor.

Blood Thinners: Hospitalised Covid-19 patients have been observed to have a very high incidence of blood clots. There is current global consensus that all hospitalised Covid-19 patients will benefit from blood thinners injected daily just under their skin (like insulin injections). Though there is sound mechanistic reasoning, randomised controlled trials are awaited.

BCG & other existing vaccines: While the world eagerly awaits a new and SARS-CoV-2-specific vaccine, the use of existing vaccines (BCG, Polio, MMR vaccines) in the hope they will work is inappropriate. Trials are under way to see if they will boost innate immunity. We know that BCG has already been given at birth to all Indians, and it does not seem to have helped keep our case numbers low.

Vitamin C: More vitamin C may have been consumed than oranges since Covid-19 began! It doesnt work.

Vitamin D: A large meta-analysis just released shows that Vitamin D does not protect against Covid-19.

Favipiravir: This is an oral antiviral drug which was fast tracked by the Indian Drug Controller but is not yet approved in the EU or US. Its use should be restricted to mild or moderate infections only. Available data to support its use is sparse but Indian trials have just been completed and the results are awaited.

Hydroxychloroquine sulphate (HCQS): We now have compelling data from multiple large clinical trials including WHOs SOLIDARITY and the UKs RECOVERY trials to categorically say: HCQS does not work. Even Donald Trump may have stopped taking it by now and so should you.

Ivermectin: This is an anti-parasitic drug widely prescribed in India and parts of South America to treat infections from worms. There is no evidence it has any role in Covid-19. It should not be used.

Miscellaneous cures: The state machinery has been used to distribute unproven herbal and Ayurvedic potions (Ukalo), homeopathic drops (Arsenicum album), and treatments peddled by god-men. Anecdotes and observations do not constitute scientific evidence. In the absence of evidence generated from rigorously vetted clinical trials, the distribution of these substances must be condemned. Pushing unproven and supposedly harmless treatments and distributing them to hundreds of thousands is not only disingenuous, but provides people false hope, and risks them lowering their guard. There are no magic pills to boost immunity to fix years of malnutrition, stunting, obesity, and chronically inflamed lungs.

Oseltamivir: This is an antiviral agent prescribed for tempering symptoms from the virus that causes influenza. It has no role in treating Covid-19 infection which is caused by a coronavirus.

Plasma: Our blood is composed of cells and plasma. Plasma from those who have recovered from Covid-19 carries naturally acquired antibodies, and, when transfused to critically ill patients with Covid-19, may help improve outcomes. This form of therapy is being used across the globe and trials to access its efficacy are under way.

Remdesivir: An intravenously administered antiviral medication, it has been shown to be effective in well-designed studies. It seems to shorten recovery time and hospital stay but does not reduce the chance of death. It is currently to be used only in hospitalised patients with severe disease.

Steroids: The only drug so far shown to have a striking impact on mortality is an old and inexpensive one. Current evidence shows that dexamethasone can reduce deaths by one-third in patients with severe Covid-19 infection who need oxygen therapy or ventilators. Their use should, however, be restricted to hospitalised patients. If they are given too soon in the course of an infection, or given to someone with only a mild infection, they could prevent the bodys own immune system from fighting the virus effectively.

Express Explainedis now onTelegram. Clickhere to join our channel (@ieexplained)and stay updated with the latest

Tocilizumab: This drug is an injection originally used in patients with rheumatoid arthritis. It is being widely used to counter the severe inflammation (cytokine storm) that occurs in some Covid-19 patients. Its use can increase the risk of bacterial infections, and it must therefore be used with caution, if at all, in carefully selected patients.

Zinc: This mineral is also commonly prescribed, despite there being no evidence that it is effective.

In conclusion, six months into the pandemic, we must therefore acknowledge four facts:

(Dr Zarir Udwadia is Consultant Chest Physician, PD Hinduja Hospital & Medical Research Centre, Mumbai. Dr Satchit Balsari is assistant professor in Emergency Medicine and in Global Health at Harvard Universitys medical and public health schools. )

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Explained News, download Indian Express App.

The Indian Express (P) Ltd

Read the original:

Explained: What works (and does not) in Covid-19 treatment - The Indian Express

As Covid-19 began to lay siege to New York Citys hospitals in March, a small but consequential debate broke out in American emergency rooms and intensive care units: Was it possible that ventilators, the much-politicized medical devices widely seen as a lifeline for severely ill Covid-19 patients, were being overused? With a pandemic poised to sweep through the U.S. and the horrific example of Italy still lingering, the dispute gained a particular urgency.

At the core of the debate was a four-letter acronym that most Americans had never heard of: ARDS, or acute respiratory distress syndrome, a harrowing lung condition that was listed on many Covid-19 death certificates. Since it was first identified half a century ago, ARDS has been mired in controversy over how to define it, how to diagnose it, and whether it should be considered a true clinical condition at all. It is because of ARDS, a diagnosis that owes its very existence to a machine, that we went into the pandemic thinking ventilators would save us. Its story serves as a cautionary tale about the dangers of prioritizing high technology and its medical paradigms in settings where one medical treatment does not fit all.

Coined in 1967 by Thomas Petty, a respiratory physician at the University of Colorado, ARDS has been a source of contention from the start. The causes of the condition were, in Pettys own words, obscure. He and three colleagues proposed the syndrome after observing a dozen patients with radically different illnesses and injuries (gunshots, pancreatitis, traffic accidents) who all presented with similar respiratory symptoms: low blood oxygen levels; fluid or other infiltrates in the lungs; and stiff lungs that didnt properly expand and contract even under mechanical ventilation.

Desperate for a solution, Petty and his colleagues put the patients on an older ventilator that blew at high pressure, even as a patient exhaled a technique he called positive end-expiratory pressure, or PEEP. The patients blood oxygen levels improved, and Petty and his colleagues felt confident that they had identified a new clinical syndrome, along with an effective treatment for it. They dispatched a paper to The New England Journal of Medicine which promptly rejected it, on the grounds that the doctors use of ventilators was unorthodox and possibly dangerous, Petty reported. The paper was rejected by two other journals before being published by The Lancet in 1967. It remains the foundational paper on ARDS and has been cited more than 4,000 times.

Although Pettys patients shared a number of common symptoms, he insisted that the patients positive response to PEEP was one of the conditions unifying traits. The ventilator, even more so than the underlying disease or injury, was crucial to the definition of the syndrome.

More than a few doctors and scientists were suspicious of the new syndrome. In a 1975 editorial, The Adult Respiratory Distress Syndrome, (May it Rest in Peace), Pettys main antagonist, pulmonologist John Murray, called ARDS a fashionable disorder, a haphazard lumping together of unrelated chest conditions, which seemed only to share a final set of symptoms. In his response, Confessions of a Lumper, Petty argued that even if you conceded Murrays point the cause of the disorder was irrelevant; the pathology was what mattered. If a disease, injury, or illness resulted in poor oxygenation, lung infiltrates, and stiff lungs, then it had to be ARDS, he wrote. Those advocating for a more nuanced diagnosis he labelled separatists.

Over the ensuing decades, even those doctors who accepted ARDS as a valid clinical condition would frequently disagree over how it should be diagnosed. In 1994, a major redefinition removed the criteria to measure the ability of the lungs to expand and contract in response to changes in pressure known as lung compliance in an attempt to standardize the disorder. In 2012, a panel of experts again redefined the syndrome, specifying that, to make a proper diagnosis, blood-oxygen levels must be measured while a patient is on PEEP. That year, an editorial in the Journal of the American Medical Association noted warily that the latest definition has essentially excluded ARDS as a possible diagnosis in patients without ventilation. The diagnosis of ARDS had become tied to the ventilator.

Pettys main antagonist, pulmonologist John Murray, called ARDS a fashionable disorder, a haphazard lumping together of unrelated chest conditions.

So this year, when Covid-19 patients began to arrive at hospitals with frighteningly low blood-oxygen levels, matching preliminary reports from China, they were funneled in droves onto ventilators.

But a 75-year-old Italian anesthesiologist and intensive care specialist, Luciano Gattinoni, along with a group of colleagues, cried foul. He noticed that Covid-19 pneumonia differed from typical ARDS in one important way: His patients blood oxygen levels were low, but many of them had no difficulty breathing on their own; their lungs were relatively compliant. That condition would come to be known as silent, or happy hypoxemia. Yet under the updated protocols, patients were being diagnosed with ARDS and quickly put on a ventilator, a harrowingly invasive procedure that involves inserting a tube down the patients throat and putting them under sedation to keep it there. Ventilators saved lives, physicians say, but they can also have considerable side effects, including lung damage.

Why do you use this kind of PEEP? Are you crazy? Gattinoni remembers counseling his younger colleagues at his hospital.

Gattinoni warned them against viewing ventilators as cure-alls and urged them to, whenever possible, supply patients with the lowest possible PEEP and gentle ventilation, as he later put it in a letter published in the American Journal of Respiratory and Critical Care Medicine. For early-stage patients, he advised non-invasive methods in the hopes of avoiding ventilation altogether. Other ICU and ER doctors related that gentler methods such as using nasal cannulas and face masks to deliver air to the lungs seemed to improve oxygen levels, STAT reported.

Gattinonis recommendations touched off considerable controversy over whether or not Covid-19 causes ARDS, whether ventilators offer the best treatment for the new disease, and how the machines should be operated. That debate is ongoing, and has split, roughly, into two camps: One side argues that conventional protocols should be followed until a detailed characterization of Covid-19 respiratory failure and its response to established ARDS therapies can be made; the other asserts that mistakes were made in the early days of the pandemic and the standard treatment should be deeply reconsidered, as Gattinoni argued in a recent rebuttal.

At the height of New Yorks pandemic in late March, an emergency room doctor at Maimonides Medical Center in Brooklyn named Cameron Kyle-Sidell posted a video on YouTube decrying the risks of relying on a medical paradigm that is untrue. Kyle-Sidells cri de coeur, which has drawn more than 800,000 views to date, now looks prescient: One study in New York City found that 88 percent of Covid-19 patients placed on ventilators died.

What was happening at the bedside was so stark that its always been hard for me to accept the possibility that somehow we werent causing a significant amount of morbidity with our initial practice, said Kyle-Sidell in a recent interview.

There is, perhaps, a moral to the story. While much of the discussion around ventilators in the early days of the Covid-19 crisis centered around their limited supply, it took time before their limited effectiveness was revealed. Doctors like Helen Ouyang, an emergency physician in New York City, reported feeling devastated by the limits of modern medicine, citing a concept most associated with combat veterans known as moral injury to describe the psychological impact on doctors as technology was failing their patients.

Robert Kacmarek, director of respiratory care at Massachusetts General Hospital, also recalled difficult times as Covid-19 exposed the limits of standardized protocols. For this kind of disease especially, you have to have individualized medicine, he said. You have to set the ventilator based on the individual pathophysiology of the patient and not based on a protocol that is designed for multitudes.

Here, earlier uses of mechanical ventilation offer a valuable lesson. In the summer of 1952, when a severe polio epidemic struck the city of Copenhagen, local medical students worked for weeks in eight-hour shifts, squeezing rubber bags to hand ventilate over 300 polio patients. The students adjusted their technique within a human context, based on clues gleaned from eye contact with their patients; the technology itself was secondary. The effects were profound. The mortality rate dropped by about half, and the episode established the value of ventilation in a way that changed the course of medicine.

By contrast, the ARDS controversy that shaded the early response to the Covid-19 pandemic exposed a disconnect between the promise of high technology and the bedside reality. The vigorous debate on the value of a half-century old diagnosis is a reminder that in medicine, no machine or protocol, however well-designed, can substitute for empathy, judgment, and evidence.

Yvan Prkachin is a historian of medicine and medical technologies, and a lecturer in the history of science at Harvard University.

Lisa De Bode is a freelance journalist and a 2019 MIT Knight Science Journalism Fellow.

View post:

Opinion: Covid-19 and Medicine's Misguided Romance With Machines - Undark Magazine

Aesthetic Medicine Market has witnessed continuous growth within the past few years and is projected to grow even more throughout the forecast period (2020 2027). The analysis presents a whole assessment of the market and contains Future trends, Current Growth Factors, attentive opinions, facts, historical information, and statistically supported and trade valid market information.

The report, titled Global Aesthetic Medicine Market defines and briefs readers about its products, applications, and specifications. The research lists key companies operating in the global market and also highlights the key changing trends adopted by the companies to maintain their dominance. By using SWOT analysis and Porters five force analysis tools, the strengths, weaknesses, opportunities, and threats of key companies are all mentioned in the report. All leading players in this global market are profiled with details such as product types, business overview, sales, manufacturing base, competitors, applications, and specifications.

You Can Request A Demo Version of Report Before Buying (Higher Preference For Corporate Email ID User): https://www.worldwidemarketreports.com/sample/298826

Allergan, Hologic, Johnson & Johnson, Galderma, Lumenis, Solta medical, Alma Laser of the major organizations dominating the global market.(*Note: Other Players Can be Added per Request)

1. Industry outlookThis is where youll find the current state of the Aesthetic Medicine industry overall and where its headed. Relevant industry metrics like size, trends, life cycle, and projected growth included here. This report comes prepared with the data to back up your business idea. On a regional basis, the Global Aesthetic Medicine market has been segmented into Asia-Pacific, North America, Europe, Latin America, and the Middle East and Africa.

2. Target marketThis target market section of study includes the following:

User persona and characteristics: It includes demographics such as age, income, and location. It lets you know what their interests and buying habits are, as well as explain the best position to meet their needs.

Market size: How big is the potential Aesthetic Medicine market for your business? It brings to light the consumption in the Aesthetic Medicine industry by the type and application.

3. Competitive analysisDiscover your competitors. The report lets you know what youre up against, but it also lets you spot the competitions weaknesses. Are there customers that are underserved? What can you offer that similar businesses arent offering? The competitive analysis contains the following components:

Direct competitors: What other companies are offering similar products and services? Which companies are your true competitors?

Competitor strengths and weaknesses: What is your competition good at? Where do they fall behind? Get insights to spot opportunities to excel where others are falling short.

Barriers to entry: What are the potential pitfalls of entering the Aesthetic Medicine market? Whats the cost of entry? Is it prohibitively high, or easy to enter?

The window of opportunity:Does your entry into the Aesthetic Medicine industry rely on time-sensitive technology? Do you need to enter early to take advantage of an emerging market?

4. ProjectionsLikewise, We offered thoughtful, not hockey-stick forecasting.

Market share:We have given the consumption behavior of users. When you know how much can your future customers spend, then only youll understand how much of the Aesthetic Medicine industry you have a chance to grab, and here we came up with real stats and numbers.

Impact Analysis of COVID-19:The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into account the political, economic, social, and technological parameters.

Finally, It is one report that hasnt shied away from taking a critical look at the current status and future outlook for the consumption/sales of these products, by the end users and applications. Not forgetting the market share control and growth rate of the Aesthetic Medicine Industry, per application. Most noteworthy, this market analysis will help you find market blind spots.

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends.

Contact Us:

Mr. ShahWorldwide Market ReportsSeattle, WA 98154,U.S.Email: [emailprotected]

See more here:

Aesthetic Medicine Market: How Much Changes Will Need to Defeat COVID 19 Effect on Industry Allergan, Hologic, Johnson & Johnson - Daily Research...

Drug firm Glenmark Pharmaceuticals on Monday said it has cut price of its antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19, by27 per cent to 75 per tablet.

Glenmark Pharmaceuticals hadlaunched FabiFlu last month at a price of 103 per tablet.

In a regulatory filing Glenmark announced a price reduction of 27 per cent for FabiFlu. The new maximum retail price (MRP) is 75 per tab, it said.

"The price reduction has been made possible through benefits gained from higher yields and better scale, as both the active pharmaceutical ingredient (API) and formulations are made at Glenmark's facilities in India, the benefits of which are being passed on to patients in the country," the filing said.

"Our internal research shows us that we launched FabiFlu in India at the lowest market cost as compared to the cost of Favipiravir in other countries where it is approved. And now we hope that this further price reduction will make it even more accessible for patients across the country," Glenmark Pharmaceuticals Senior Vice President and Head India business Alok Malik said.

Further, the company has commenced a post marketing surveillance (PMS) study on FabiFlu to closely monitor the efficacy and safety of the drug in 1,000 patients that are prescribed with the oral antiviral, as part of an open label, multicenter, single arm study, the filing added.

"We expect this post marketing surveillance study to shed more light on the drug's clinical effectiveness and safety in a large cohort of patients prescribed FabiFlu," Malik added.

On June 20, Glenmark announced that it received manufacturing and marketing approval from India's drug regulator for FabiFlu, making it the first oral Favipiravir-approved medication in India for the treatment of mild to moderate COVID-19.

Glenmark has also completed the phase 3 clinical trial with Favipiravir (FabiFlu) in mild to moderate COVID-19 patients in India. The trial results will be available shortly, the company said.

Glenmark is also conducting another phase 3 clinical trial to evaluate the efficacy of two antivirals drugs Favipiravir and Umifenovir as a combination therapy in moderate hospitalised adult COVID-19 patients in India.

Shares of Glenmark Pharma were trading 1.34 per cent lower at 421.00 apiece on BSE. PTI SVK DRR DRR

Subscribe to newsletters

* Enter a valid email

* Thank you for subscribing to our newsletter.

See the original post:

COVID-19 medicine price reduced to 75 per tablet by Glenmark Pharma - Livemint

Norman Swan: Over the last week the ABC has been focusing on your mental health and offering practical evidence-informed advice on what we can all do to get through this COVID-19 pandemic as best we can. So what role could laughter play? There is nothing new about the idea of using laughter as a mood booster. Even the King James Bible preaches that 'a merry heart doeth good like a medicine'. But can laughter therapies really help alleviate the stress, anxiety and depression that many of us are experiencing right now?

The Health Report's David Murray has been investigating.

David Murray: Chances are you probably don't feel much like laughing right now. But maybe in this moment, laughter is exactly what we need more of.

Dan Illic: Laugh at the pandemic, at the way we are all living due to the pandemic. If you don't, you actually might cry.

David Murray: Dan Illic is a satirist and comedy writer. If you got a chuckle out of watching Ray Martin on At Home Alone Together, well, you can thank Dan for bringing you that. And he reckons that right now people really want something to laugh at.

Dan Illic: I must have seen five or six live streams by comedians from their own living rooms. Some of them had audiences between 60 and 300 people on Zoom, and that's incredible. Also there is so much great comedy happening on Instagram and TikTok, incredibly funny stuff, impersonating world leaders, making fun of the restrictions. It ends up being able to dissolve tension, absorb much of the fear around the world we are living in in this pandemic land right now.

David Murray: Comedy is great, obviously, but sometimes it's just as likely to elicit a groan as it is a giggle. So what about laughter itself? We are often told it's the best medicine, but can it get us through this pandemic with our mental health intact?

This is a laughter therapy session. Usually it would be held in person, but just like everything else during the pandemic it has also gone online.

Ros Ben-Moshe: I felt very enlivened, a real elevation in my spirit.

David Murray: Ros Ben-Moshe is an adjunct lecturer in health promotion at La Trobe University. She also runs laughter well-being programs, sometimes called Laughter Yoga.

Ros Ben-Moshe: There are two different types of laughter therapy. There is a humour-based laughter therapy, so that's something that we would get from laughing together with friends or at a funny video, then there is non humour based laughter therapy which is where Laughter Yoga comes in.

David Murray: So, no jokes, no comedians, you just laugh.

Ros Ben-Moshe: The way that it works is the facilitator demonstrates a particular laughter exercise, so it might be a greeting laugh, like [laughs]. Initially that might seem a little silly or strange to people but people just lose themselves to laughter very, very soon.

David Murray: Basically this kind of Laughter Yoga relies on fake laughter, at least at the beginning. But studies have still linked it to the release of endorphins, the dilation of blood vessels, relaxing tense muscles, forcing you to breathe and kind of leaving you feeling like you've just done some exercise. It all sounds pretty good, but is this kind of laughter really the best medicine if you need a bit of help with your mental health?

Natalie van der Wal: I have to be honest, it started because I am a yoga teacher for many years.

David Murray: Natalie van der Wal is an Associate Professor in Cognitive and Social Psychology at Leeds University in the UK. Recently she has been looking into the research on laughter therapies and what the available studies actually say about laughter and its potential for alleviating stress, depression and anxiety. But she is the first to admit that when she started the project she wasn't exactly impartial.

Natalie van der Wal: A friend of mine, he's a Laughter Yoga leader, and I did a course with him to become a Laughter Yoga leader myself. So in the beginning I was little bit biased, but then my co-author, Robin Cok, he is actually super-critical, so my initial positive outlook got very realistic.

David Murray: Associate Professor van der Wal and her co-author collected 86 relevant studies across both humour and non humour based laughter therapies. I have to say that overall they weren't exactly impressed with the quality of the research. They say many studies didn't use control groups and relied on small sample sizes. Others showed a high risk of bias. And then there was the results on the efficacy of the therapy itself, which were, well, a bit mixed.

Natalie van der Wal: We found that laughter therapy significantly reduces your depression, that was the strongest outcome, but there were a little bit more mixed results for anxiety and stress. So there I cannot say as a scientist there is a real effect. It looks like it but I cannot say for 100% sure.

David Murray: Now, the reason for this comes down to statistics. I know, I know, stay with me here. Many of the studies included in this meta-analysis did conclude that laughter therapy helped reduce stress and anxiety. But according to Natalie van der Wal, when you look beyond the averages and include their confidence intervals (this is the range of values that you are fairly sure your true result lies in), then the positive effects for stress and anxiety potentially disappear.

Natalie van der Wal: You would really want to see that the complete confidence interval is below zero, and that is not the case for the majority of the studies.

David Murray: But here's the other interesting thing, while you might assume that natural organic laughter would be better for you, it was the non humour based therapies that had the greater effect on mental health. Ros Ben-Moshe says this could be because when you are not waiting for something to make you laugh, you actually laugh more. But does this really matter when the overall evaluation of laughter therapy studies was kind of disappointing? Well, Associate Professor van der Wal said we shouldn't be giving up on the idea of laughter as medicine just yet.

Natalie van der Wal: For me it's simple; if you laugh, you feel better. But if we have more research, like big large randomised control trial studies, then we can have a final say about it. At the moment we just don't have enough evidence.

David Murray: So in the meantime if laughing makes you feel better, go for it. While we can't say it's necessarily the best medicine, it certainly can't hurt.

Norman Swan: A bit of laughter there from the late southern gospel singer George Younce, finishing that report from David Murray.

More here:

Is laughter really the best medicine? - Health Report - ABC News

Nuclear Medicine Imaging Equipment Market Analysis report studies latest market trends, development aspects, market gains and market scenario during the forecast period.

Latest Report published by Global Marketers titled: Global Nuclear Medicine Imaging Equipment Market Analysis report studies latest market trends, Market Share, development aspects, market gains and market scenario during the Forecast period 2019-2027. This study gives a comprehensive and detailed analysis of current and future 5-6 years market analyzed data of major players demanding on global market. The report explores key statistics on the Nuclear Medicine Imaging Equipment market status of the global and united states major industry players in detail.

Get Full Sample Report Including The In-depth Details: @ https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-nuclear-medicine-imaging-equipment-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/147927#request_sample

The Major Players Operating In Nuclear Medicine Imaging Equipment Market:

Shenzhen Anke High-TechFujifilm CorpPositron CorpNeusoft Medical SystemsHitachi Medical CorpCarestreamFonar CorpGE HealthcareMindray Medical International LTDParamed Medical SystemsECHO-SON S.A.Hologic IncSiemens HealthcareEsaote S.P.A.Philips Healthcare

It gives an detailed overview of the market, current trends, future 6 YEAR roadmap, Market challenges, industry environment, and also describes the industry chain structure & opportunities in the current market. This report Provides in-depth analysis of the scope of current and future market including the major factors such as Revenue forecast, company share, competitive landscape, growth factors, and trends, SWOT analysis i.e. Strength, Weakness, Opportunities, and Threat to the industry. In addition, this report introduces market competition status among the merchants and company outline, besides, market demand analysis and value chain features are covered in this report.

Note: Upto 30% Discount On 2020 Reserch Report

Ask For Discount: https://www.globalmarketers.biz/discount_inquiry/discount/147927

Significant Features Of Nuclear Medicine Imaging Equipment Report: :

Continue..

Customization Avaliable

Do you want any other requirement or customize the report, Do Inquiry Here: https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-nuclear-medicine-imaging-equipment-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/147927#inquiry_before_buying

Global Nuclear Medicine Imaging Equipment Market Split By Product Type And Applications :

By Type:

SPECT EquipmentPET-CT Equipment

By Application:

DiagnoseTreatment

Nuclear Medicine Imaging Equipment Market Report Scope:

Table of Contents

Global Nuclear Medicine Imaging Equipment Market Research Report 2020 2027

For more Information or Browse the complete report @ https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-nuclear-medicine-imaging-equipment-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/147927#table_of_contents

Continued here:

Global Nuclear Medicine Imaging Equipment Market Professional Research By Regions, Types and Analysis of Key Players- Research Forecasts to 2027 -...